| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.32 | 8e-22 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.3 | 1e-19 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.21 | 4e-10 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.2 | 7e-09 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.2 | 1e-08 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.16 | 3e-07 |
| mRNA | Pazopanib | FIMM | pan-cancer | AAC | 0.81 | 5e-07 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-06 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-06 |